Anti-bacterial vaccine compositions
View Patent ↗Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
1. An attenuated Pasteurellaceae bacterium selected from the group consisting of Pasteurella ( Mannheimia ) haemolytica, Pasteurella multocida , and Actinobacillus pleuropneumoniae comprising a mutation in a polynucleotide sequence that encodes an atpG polypeptide comprising an amino acid sequence at least 70% identical to the atpG amino acid sequence of SEQ ID NO: 167, wherein the mutation results in decreased virulence and attenuation of the bacterium.
2. The bacterium of claim 1 , wherein the mutation results in deletion of all or part of the polynucleotide sequence that encodes the atpG polypeptide.
3. The bacterium of claim 1 , wherein the mutation results in an insertion in the polynucleotide sequence that encodes the atpG polypeptide.
4. The bacterium of claim 1 , that is a Pasteurella ( Mannheimia ) haemolytica bacteria.
5. An immunogenic composition comprising the bacterium according to any one of claims 1 , 2 , 3 , and 4 .
6. A vaccine composition comprising the immunogenic composition according to claim 5 and a pharmaceutically acceptable carrier.
7. The vaccine composition according to claim 6 , further comprising an adjuvant.
8. An attenuated Pasteurellaceae bacterium selected from the group consisting of Pasteurella ( Mannheimia ) haemolytica, Pasteurella multocida , and Actinobacillus pleuropneumoniae comprising a mutation in a polynucleotide sequence that encodes an atpG polypeptide, wherein the polynucleotide sequence hybridizes to the complement of a polynucleotide sequence set forth in SEQ ID NO: 166 under stringent conditions, such conditions comprising a final wash in buffer comprising 2×SSC/0.1% SDS, at 35° C. to 45° C.
9. The bacterium of claim 8 , wherein the mutation is in the polynucleotide sequence set forth in SEQ ID NO: 166.
10. An immunogenic composition comprising the bacterium according to claim 8 or 9 .
11. A vaccine composition comprising the immunogenic composition according to claim 10 and a pharmaceutically acceptable carrier.
12. The vaccine composition of claim 11 further comprising an adjuvant.